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Background: The estimated intake of soy isoﬂavones from a meal has been based on the content in a
food, but the health effects of soy isoﬂavones are possibly affected by their bioavailability. In this study
we have evaluated the isoﬂavone bioavailability after the intake of three kinds of soy foods and a
commercial soy isoﬂavone supplement, and examined whether the isoﬂavone bioavailability is different
between equol producers and non-producers.
Methods: Healthy female subjects (n ¼ 20; 9 equol producers, 11 equol non-producers) aged between 20
and 26 y participated in this study. To assess the bioavailability of isoﬂavones, equol producers and non-
producers consumed three kinds of soy foods (tofu, fermented soybeans: natto in Japanese, soy milk) and
a soy isoﬂavone supplement containing 75 mg isoﬂavones together with breakfast. Urine was collected
for 24 h, and the amounts of urinary excretions of daidzein, genistein, and the metabolite equol were
measured. The intra- and inter-individual variations in the bioavailability of isoﬂavones were also
examined.
Results: The bioavailability of daidzein following the consumption of tofu, natto, soy milk, and soy iso-
ﬂavone supplement were 66.9%, 45.2%, 65.7%, and 57.9%, respectively, and the bioavailability of genistein
following the consumption of these soy products were 33.7%, 24.4%, 31.2%, and 17.7%, respectively. The
bioavailability of daidzein and genistein was signiﬁcantly greater in equol non-producers than equol
producers, especially following the consumption of soymilk. In the equol producers, the 24 h urinary
excretion of equol was signiﬁcantly greater after the intake of soy isoﬂavone supplement than after the
intake of natto or soymilk. The analysis of relative reliability of intra- and inter-individual variations
suggested that bioavailability of isoﬂavones is less variable following soymilk intake than soy isoﬂavone
supplement.
Conclusions: The results in this study suggest that bioavailability of isoﬂavones are different between
equol producers and non-producers, because the 24 h urinary excretion of equol in the equol producers
were signiﬁcantly lower than those in the equol non-producers.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction quantity of ingredient absorbed and its bioavailability [4]. There is aMany studies have reported the beneﬁcial health effects of
isoﬂavones on estrogen-related cancer, cardiovascular disease, lipid
proﬁles, climacteric symptoms, and osteoporosis in humans [1e3].
However, the health effects of soy isoﬂavones are dependent on theonal and Environmental Sci-
a-Ku, Shizuoka-Shi, Shizuoka
oda).
Inc. This is an open access article uwide variation in the reported proportion of urinary isoﬂavone
excretion that is not apparently dependent on the dose. Different
factors have been suggested to inﬂuence the bioavailability of iso-
ﬂavones; however, the results are inconsistent, probably due to the
use of different study designs, isoﬂavone sources, or food matrices
between and within studies [5].
Soybean and related products are one of the richest sources of
isoﬂavones, which act as a phytoestrogen in humans [6]. The iso-
ﬂavones genistein and daidzein are present as glucosides in soy and
many unfermented foods. The isoﬂavone content of soybean has
been reported as follows: genistein 50%: daidzein 40%: glycitein 10%nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cosides and malonylglucosides, but also as acetylglucosides and
aglycones [8,9]. In the human intestine, isoﬂavone glycosides pre-
sent in soy products can be deglycosylated by b-glucosidases in the
human small intestine [10]. Bacterial metabolism of soy isoﬂavones
varies among individuals. Inter-individual differences in
phytochemical metabolism and disposition may be affected by gut
microbial identity and activity, stability, and variation in concen-
trations of endogenous compounds that modulate biotransforma-
tion pathways [11,12]. Gut bacterial modiﬁcation of soy isoﬂavones
produces metabolites that differ in biological activity from the
parent compounds [13]. The predominant daidzein metabolites
produced by human intestinal bacteria are dihydrodaidzein, equol,
and o-desmethylangolensin (O-DMA) [8]. Observational studies
suggest that the O-DMA-producer and equol-producer phenotypes
are independent of each other, i.e., the capacity to harbor O-
DMAeproducing bacteria is not inﬂuenced by whether the indi-
vidual has the capacity to harbor equol-producing bacteria [14]. The
daidzein precursor is needed for the production of O-DMA, and the
half-life of O-DMA in the body is short [15].
Equol is a potent antioxidant and its clinical importance has
recently become a subject of interest. Among humans, inter-
individual differences in daidzein metabolism exist following soy
or daidzein consumption; approximately 30%e50% of the human
population produces equol and approximately 80%e90% produces
O-DMA. Several large sample size studies have indicated that only
25e30% of the adult population of Western countries produces
equol when they consume soy foods containing isoﬂavones [11,16].
This proportion is signiﬁcantly lower than the reported proportion
of 50e60% of equol producers in adults from Japan, Korea, and China
or in Western adult vegetarians [12]. Notably, the source of iso-
ﬂavones consumed is important for evaluating their physiological
activities.
Clinical studies on the bioavailability of various forms of soy
isoﬂavones (as extractives, food additives, or natural soy foodstuffs)
have been undertaken in different populations (e.g., Asians and
Europeans) [17e21]. However, these results have been inconclu-
sive, and it is difﬁcult to draw a conclusion due to differences in
study populations, isoﬂavone origin, form, dose, and the meals
consumed concurrently [22]. Further, the majority of research did
not provide sufﬁcient explanation of the controlledmeal consumed
simultaneously with the isoﬂavones.
While several studies reported bioavailability of isoﬂavones, data
regarding physiological inter- or intra-individual variations of iso-
ﬂavones availability are scarce. In dietary surveys, the intake of soy
isoﬂavones from natural soy foods is estimated based on the refer-
ence values of isoﬂavone content [23e25] (available in food
composition tables). Furthermore, a truer estimation of isoﬂavone
intake, therebyenabling thedeterminationof their health effects and
the proper planning of the isoﬂavone intervention, is thought
possible by taking intra- and inter-individual variations in bioavail-
ability into account. Therefore, it is necessary to quantify inter- and
intra-individual variations in isoﬂavone bioavailability under condi-
tions of standardized daily food intake to fully consider the possible
metabolic consequenceof ingested isoﬂavones. In this study,wehave
evaluated the 24 h urinary excretion of isoﬂavones, in equol pro-
ducers andnon-producers, following the consumption of various soy
products simultaneously with the meals in Japanese population.
2. Materials and methods
2.1. Subjects
The subjects were recruited from students in Tokoha University.
Twenty healthy young adult Japanese women, aged 20e26 yearswith a body mass index of 18.6e29.1 kg/m2 (mean ± SD:
23.3 ± 3.7 kg/m2) were recruited to participate in the four studies.
Before the start of the study, the subjects attended group orienta-
tions where the study purpose and protocol were explained. All
volunteers provided written informed consent. All individuals re-
ported no medication use and had no allergies to soybean. The
study protocol was approved by the ethics committee of Tokoha
University in accordance with the Helsinki Declaration and the
Committee's own guidelines (1964 approval, modiﬁcation).
2.2. Study design
Among the 20 subjects, 15 subjects participated in the study of
the bioavailability of 4 soy products, and another 5 subjects
participated in the three times repeated trial (soy milk and sup-
plement) for intra-individual variation according to the same
protocol.
The study consisted of four feeding days, each of which was
separated by more than one week as a washout period. All subjects
were asked to avoid any soy foods and products, and complete a
daily dietary record on the previous day. On the trial days, subjects
were instructed to eat all of the basal test diet provided. The basal
test diet consisted of a meal that did not include soy isoﬂavones.
The other nutritive components were established according to the
recommended dietary allowance (RDA) using the Japanese DRIs
(Dietary References Intakes for Japanese, 2010).
The soy isoﬂavone supplement (Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan) contained 75 mg isoﬂavones, and other soy products
also contained 75 mg isoﬂavone equivalent by references, i.e, 180 g
of tofu, 100 g of fermented soybeans, hereafter referred to as natto,
and 300 g of soy milk (Table 1). On the trial day, subjects consumed
either one of each soy foods or soy isoﬂavone supplement together
with the breakfast meal, which was served as a basal diet, and the
consecutive meals were taken in a dining room at the designated
time.
2.3. Quantitative analysis of soy foods, supplement, and the basal
diet
To determine isoﬂavones contents in soy products, samples of
tofu, natto and soymilk were freeze-dried with the exception of the
supplement, which was crushed and used as the analytical spec-
imen. Three samples were analyzed, and the mean values were
calculated. HPLC analysis of the ﬂavonoid content of foods was
performed according to the procedures of Sakakibara et al. [26].
Fifty milligrams of dried sample was placed in a test tube with
ground glass stopper and mixed with 5 mL of citrate phosphate
buffer (pH 4.6) containing 10 mg b-glucosidase (37 units). The
sample was hydrolyzed at 37 C for 4 h, and 5 mL of ethanol was
added. After centrifugation for 10 min, 8 mL of the supernatant was
dried in a vacuum evaporator. Deconjugation was performed using
b-glucosidase/sulfatase according to the modiﬁed method of King
et al. [27]. The dietary isoﬂavones were analyzed using HPLC
(SHIMADZU, Kyoto, Japan) equipped with a diode array detector
(260 nm). The compounds were identiﬁed by retention times and
spectra in comparison with standards and quantiﬁed by the peak
area. The analyzed results indicated that soy isoﬂavones were ab-
sent in the basal diet.
2.4. Sample collection and urinary isoﬂavone analysis
The subjects ate breakfast in the dining room on the test day,
and ingested the soy foods or soy isoﬂavone supplement containing
the identical amounts of isoﬂavones. Urine samples were collected
at ﬁxed time points (0, 2, 6, 12, 24 h) after ingestion of the test food.
Table 1
Isoﬂavone contents of soy products.
Soy products
Tofu Fermented soybeans (natto) Soymilk Supplement
Tested of food intake (g) 180 100 300 0.075
Daidzein
Total (mg) 24.6 ± 2.69 41.1 ± 4.46 14.2 ± 2.99 23.3 ± 2.40
Aglycone (aglycone%) 33.8 30.1 3.8 92.6
Genistein
Total (mg) 14.5 ± 1.75 22.5 ± 2.78 14.3 ± 2.38 29.6 ± 2.21
Aglycone (aglycone%) 29.6 8.3 2.7 88.4
Total amount of isoﬂavones (mg) 39.1 ± 4.44 63.6 ± 7.19 36.7 ± 4.10 52.9 ± 4.58
All values are presented as means of three replicates of each soy product analyzed.
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ples were collected using a U-Container (Akita Sumitomo Bakelite
Co., Ltd., Akita, Japan). Following collection of the urine sample, the
volume of the sample was measured. The urine samples were
stored at 20 C until analysis. Urinary daidzein, genistein, and
equol contents were determined using a modiﬁed version of the
LC-MS methods previously described by Shimoi et al. [28].
Urine samples (0.5 mL) were mixed with 0.5 mL sodium acetate
buffer (pH 4.5), preincubated at 37 C, and then incubated with b-
glucuronidase/sulfatase at 37 C for 20 min. The urine and incu-
bation medium were acidiﬁed with the same volume of 0.01 M
oxalic acid, and the solution was applied to a Sep-Pak C18 cartridge
(Waters Co., Milford, MA). After washing the cartridge with 0.01 M
oxalic acid, methanol/water/0.5 M oxalic acid (25:73:2, v/v), and
distilled water, the methanol eluate was obtained. The eluate was
evaporated to dryness, and the residue was dissolved in 200 mL of
methanol. The solutions were analyzed chromatographically using
a HPLC system (SHIMADZU). The LC conditions were as follows:
column, Capcell Pak C18-UGI120 (250  4.6 mm I.D., Shiseido,
Tokyo, Japan); detection, daidzein UV 250 nm, genistein UV
260 nm, equol UV 280 nm; ﬂow rate, 0.7 mL/min; mobile phase,
Solvent A: methanol with 0.03% triﬂuoroacetic acid, Solvent B:
distilled water with 0.03% triﬂuoroacetic acid. The analysis was
carried out at 50 C.
Quantiﬁcation of each isoﬂavone was carried out using peak
areas according to calibration curves of the peak area of standards
at various concentrations. HPLC standards were purchased from
Wako Pure Chemical Industries, Ltd., Osaka, Japan (daidzein, gen-
istein) and Funakoshi Co., Ltd., Tokyo, Japan (equol). All solvents
and chemicals used were of HPLC analytical grade.
2.5. Statistical analysis
Data analysis was carried out using IBM SPSS Statistics for
Windows, Version 22.0 (IBM Corp., Armonk, NY, USA). Means and
standard deviations were analyzed using descriptive statistics. Data
distribution was expressed using quartile distributions. Analysis of
variance test for normality was compared using the Shapiro-Wilk
normality test. The distribution of each isoﬂavone was tested for
normality before analysis, and skewed variables were log trans-
formed. Comparison of urinary excretion among 4 soy products was
analyzed using Kruskal-Wallis test, and comparison of the
bioavailability in equol-producers and non-producers was analyzed
using Mann-Whitney U test.
Intra- and inter-individual variations were calculated with
analysis of variance using mean ± standard deviation (SD). Intra-
individual (within-individual) variations (CVw ¼ SDw/Mean of
urinary excretion in 4 or 3 soy foods  100) and inter-individual
(between-individual) variations (CVb ¼ SDb/Mean of urinary
excretion in each same soy food  100) were calculated using theformula provided by Beaton [29]. The CVw (within-individual
variation) was calculated to estimate the true intake, dividing the
subjects into equol-producers and non-producers. The relative
reliability of intra- and inter-individual variations was evaluated
using the intraclass correlation coefﬁcient (ICC) calculated from the
individual internal variance and the between individuals variance.
The following formula was used to calculate ICC: s2B/(s2W þ s2B)
[between-subject variance/(within-subject variance þ between-
subject variance)]. ICC was evaluated according to the valuation
basis of Rosner [30] as follows: “0.75  ICC” is “excellent repro-
ducibility” and “0.4  ICC<0.75” is “fair to good reproducibility”.
3. Results
The isoﬂavone contents of tofu, natto, soy milk, and the soy
isoﬂavone supplement used in this study are presented in Table 1.
The soy isoﬂavone supplement contained a greater proportion of
isoﬂavone aglycones than the other soy products.
The 24 h urine excretion after soy food intake was collected at
various time points. The total numbers of samples obtained for the
24 h urine analysis, excluding those subjects who failed urine
collection or those who refused to consume natto, were 71 in total
(15 for tofu, 16 for natto, 20 for soy milk, and 20 for soy isoﬂavone
supplement). The urinary excretions of daidzein and genistein
isoﬂavones were expressed as the proportion to those of respective
isoﬂavones consumed as the soy products. Maximal excretions of
daidzein and genistein were observed during the period of 6e12 h,
and the urinary excretion of daidzein and genistein was much
smaller during the period of 12e24 h in all groups following the
consumption of soy products (Figs. 1 and 2).
The proportions of 24 h urinary excretions of daidzein to the
amounts of daidzein consumed from tofu, natto, soy milk, and soy
isoﬂavone supplement were 66.9%, 45.2%, 65.7%, and 57.9%,
respectively in average (Fig. 3). The proportions of 24 h urinary
excretions of genistein to the amounts of genistein consumed from
tofu, natto, soy milk, and soy isoﬂavone supplement were 33.7%,
24.4%, 31.2%, and 17.7%, respectively in average (Fig. 3). There was
no signiﬁcant difference in the proportion of daidzein recovered in
24 h urine among the groups following the consumption of
different soy products. The proportion of genistein recovered in
24 h urine following the consumption of soymilk tended to be
greater than those in 24 h urine following the consumption of other
soy products, and it was signiﬁcantly greater than that after the
consumption of soy isoﬂavone supplement (p < 0.05; Fig. 3).
The proportions of 24 h urinary excretions of daidzein and
genistein to the amounts of respective isoﬂavone consumed from
soymilk were signiﬁcantly greater in equol non-producers than
equol producers (p < 0.05), whereas no signiﬁcant differences
between equol non-producers and equol producers were observed
in the urinary excretions of daidzein and genistein after
Fig. 1. Distribution of urinary daidzein excretion levels after ingestion of soy foods and the supplement in the four soy product. Box-and-whisker plot indicates a quartile dis-
tribution (Upper ¼ 75th percentile, Lower ¼ 25th percentile, Middle ¼ 50th percentile). The lowest datum is within the 1.5 interquartile range of the lower quartile and the highest
datum is within the 1.5 interquartile range of the upper quartile.
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(Table 2.). In the equol producers, the proportion of 24 h urinary
excretions of equol to the amounts of daidzein consumed from soy
isoﬂavone supplement was signiﬁcantly greater than those
following the consumption of natto or soymilk (p < 0.05; Table 2.).
The inter-individual variations in the proportions of 24 h urinary
excretions of daidzein and genistein to the amounts of respective
isoﬂavone consumed from soy products were 45.3% and 53.8%,
respectively in average. The intra-individual variations in the pro-
portions of 24-h urinary excretions of daidzein and genistein to the
amounts of respective isoﬂavone consumed from soy products
were 36.1% and 38.4%, respectively in average. The intra-individual
variations in the proportions of 24 h urinary excretions of daidzein
and genistein in equol producers were 43.5% and 37.1%, respec-
tively, whereas those in equol non-producers were 30.2% and
39.3%, respectively. The analysis of relative reliability of intra- andinter-individual variations using ICC showed that daidzein and
genistein values for the groups following the consumption of soy-
milk were 0.95 and 0.89, respectively, which indicated “excellent
reproducibility”, while the daidzein and genistein values for the
groups following the consumption of soy isoﬂavone supplement
were 0.54 and 0.44, respectively, which indicated “fair to good
reproducibility.”
4. Discussion
The bioavailability of isoﬂavones from the daily diet may be
variable, because most soy isoﬂavones in soy foods are bound with
proteins, sugars, or other compounds. In this study, we attempted
to estimate the bioavailability of isoﬂavones from three kinds of soy
foods, which are popular and widely available in Japan, i.e., tofu,
natto (fermented soybeans) and soymilk, by measuring the urinary
Fig. 2. Distribution of urinary genistein excretion levels after ingestion of soy foods and the supplement. Box-and-whisker plot indicates a quartile distribution (Upper ¼ 75th
percentile, Lower ¼ 25th percentile, Middle ¼ 50th percentile). The lowest datum is within the 1.5 interquartile range of the lower quartile and the highest datum is within the 1.5
interquartile range of the upper quartile.
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and an isoﬂavone metabolite equal during the 24-h period
following the intake of soy products along with breakfast. It has
been shown that urinary excretions of daidzein and genistein after
intake of soy-based food and soya-based supplement are maximal
between 6 and 12 h, and more than 70% of urinary excretions are
completed by 24 h [31]. Indeed, our results showed that maximal
excretions of daidzein and genistein were observed during the
period of 6e12 h, and the urinary excretion of daidzein and gen-
istein was much smaller during the period of 12e24 h in all groups
following the consumption of soy products. Thus, we computed the
proportions of 24 h urinary excretions of daidzein and genistein to
the amounts of respective isoﬂavones consumed from tofu, natto,
soy milk, and soy isoﬂavone supplement, as indices of bioavail-
ability of daidzein and genistein from the soy products. In this
study, we have demonstrated that the bioavailability of daidzein
following the consumption of tofu, natto, soy milk, and soyisoﬂavone supplement was relatively greater, ranging between 45%
and 67% as assessed by the 24-h urinary excretion, and less variable
than the bioavailability of genistein, which ranged between 17%
and 34%.
Isoﬂavones in soy products have antioxidant properties and act
as phytoestrogens. Equol is a potent antioxidant in vitro (Wiseman
et al. [29]), and its clinical importance has recently been of interest.
The clinical importance of equol as an isoﬂavone metabolite has
been reported, providing clues to the effectiveness of soy and its
metabolites [11]. In this study we found that the 24 h urinary
excretion of equol, as estimated from 24-h urinary excretion, was
signiﬁcantly greater after the intake of soy isoﬂavone supplement
than after the intake of natto or soymilk. It is interesting to note
that the bioavailability of daidzein and genistein was signiﬁcantly
greater in equol non-producers than equol producers, especially
following the consumption of soymilk. Thus, it is likely that the 24 h
urinary excretion of equol in the equol producers is variable among
Fig. 3. Distribution of 24 h urinary isoﬂavone excretion levels after ingestion of soy foods and the supplement. Box-and-whisker plot indicates a quartile distribution (Upper ¼ 75th
percentile, Lower ¼ 25th percentile, Middle ¼ 50th percentile). The lowest datum is within the 1.5 interquartile range of the lower quartile and the highest datum is within the 1.5
interquartile range of the upper quartile. a: Signiﬁcant difference using Bonferroni's test with p < 0.05.
Table 2
24 h urinary isoﬂavone excretion of equol producers and non-producers.
Tofu Natto Soymilk Supplement
Equol
Producers
(n ¼ 4)
Non-producers
(n ¼ 11)
Producers
(n ¼ 8)
Non-producers
(n ¼ 8)
Producers
(n ¼ 9)
Non-producers
(n ¼ 11)
Producers
(n ¼ 9)
Non-producers
(n ¼ 11)
Daidzein
(mg/mg intake)
0.43 ± 0.63
(0.33e0.53)#
0.66 ± 0.14
(0.56e0.76)
0.39 ± 0.12
(0.29e0.49)
0.51 ± 0.12
(0.42e0.61)
0.54 ± 0.37
(0.31e0.76)
0.85 ± 0.29*
(0.62e1.09)
0.48 ± 0.19
(0.32e0.63)
0.66 ± 0.13
(0.56e0.76)
Genistein
(mg/mg intake)
0.19 ± 0.04
(0.13e0.25)
0.40 ± 0.31
(0.17e0.62)
0.19 ± 0.10
(0.11e0.28)
0.30 ± 0.11
(0.20e0.39)
0.26 ± 0.16
(0.16e0.36)
0.40 ± 0.16*
(0.27e0.53)
0.16 ± 0.09
(0.08e0.23)
0.19 ± 0.06
(0.15e0.24)
Equol
(mg/mg intake)
0.50 ± 0.26a,b
(0.28e0.71)
Not detected 0.21 ± 0.14a
(0.12e0.29)
Not detected 0.27 ± 0.14a
(0.14e0.39)
Not detected 0.47 ± 0.09b
(0.33e0.62)
Not detected
Values are mean ± SD.
* Equol producers vs equol non-producers after intake of each soy products using Mann-Whitney U test (P < 0.05).
# Values are 95% conﬁdence intervals.
a-b Values not sharing a common alphabet are signiﬁcantly different from each other at (P < 0.05) by Kruskal-Wallis test.
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In the present study, the analysis of relative reliability of intra-
and inter-individual variations revealed that bioavailability of soy
isoﬂavone supplement is more variable following soy isoﬂavone
supplement isoﬂavones than soymilk intake. The greater intra-
individual variations of bioavailability of isoﬂavones from soy iso-
ﬂavone supplement may be related with the greater contents of
isoﬂavone aglycones. Isoﬂavone aglycones are thought to be
absorbed more efﬁciently than isoﬂavone glucosides.
Wiseman et al. reported that although intra-individual variation
in isoﬂavone metabolism was low, inter-individual variation was
high [29]. It should be noted that the individual variation (CV%) of
the 24 h urinary isoﬂavone excretion differed among the various
soy foods and the supplement consumed by the subjects.
In the present study, we attempted to evaluate the reproduc-
ibility of our data in this study using ICC (intraclass correlation
coefﬁcient). According to the evaluation criteria by Rosener et al.
[31], values over 0.8 indicate excellent reproducibility, and values
0.7 indicate good reproducibility. The ICC of daidzein and genistein
for soymilk were computed as 0.95e0.859. These results suggest
that the data of soymilk are more reliable than the data of soy
isoﬂavone supplement, with daidzein ICC values of 0.95 for soy
milk and 0.54 for supplement, and with genistein ICC values of 0.89
for soy milk and 0.44 for supplement.In conclusions, the results in this study suggest that bioavail-
ability of isoﬂavones are different between equol producers and
non-producers.
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